EP1858546A4 - Modified transferrin fusion proteins - Google Patents

Modified transferrin fusion proteins

Info

Publication number
EP1858546A4
EP1858546A4 EP06736868A EP06736868A EP1858546A4 EP 1858546 A4 EP1858546 A4 EP 1858546A4 EP 06736868 A EP06736868 A EP 06736868A EP 06736868 A EP06736868 A EP 06736868A EP 1858546 A4 EP1858546 A4 EP 1858546A4
Authority
EP
European Patent Office
Prior art keywords
fusion proteins
transferrin fusion
modified transferrin
modified
proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06736868A
Other languages
German (de)
French (fr)
Other versions
EP1858546A2 (en
Inventor
Homayoun Sadeghi
Andrew J Turner
Christopher P Prior
David J Ballance
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biorexis Pharmaceutical Corp
Original Assignee
Biorexis Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biorexis Pharmaceutical Corp filed Critical Biorexis Pharmaceutical Corp
Publication of EP1858546A2 publication Critical patent/EP1858546A2/en
Publication of EP1858546A4 publication Critical patent/EP1858546A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/644—Transferrin, e.g. a lactoferrin or ovotransferrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EP06736868A 2005-03-04 2006-03-06 Modified transferrin fusion proteins Withdrawn EP1858546A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US65814005P 2005-03-04 2005-03-04
US66375705P 2005-03-22 2005-03-22
PCT/US2006/007617 WO2006096515A2 (en) 2005-03-04 2006-03-06 Modified transferrin fusion proteins

Publications (2)

Publication Number Publication Date
EP1858546A2 EP1858546A2 (en) 2007-11-28
EP1858546A4 true EP1858546A4 (en) 2009-03-04

Family

ID=36953883

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06736868A Withdrawn EP1858546A4 (en) 2005-03-04 2006-03-06 Modified transferrin fusion proteins

Country Status (4)

Country Link
EP (1) EP1858546A4 (en)
JP (1) JP2008531059A (en)
CA (1) CA2599723A1 (en)
WO (1) WO2006096515A2 (en)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8129504B2 (en) 2001-08-30 2012-03-06 Biorexis Technology, Inc. Oral delivery of modified transferrin fusion proteins
DK2049560T3 (en) 2006-07-13 2013-07-29 Novozymes Biopharma Dk As Process for the preparation of particles of proteinaceous material
KR101193722B1 (en) 2006-07-24 2013-01-11 바이오렉시스 파마슈티칼 코포레이션 Exendin fusion proteins
WO2008021412A2 (en) * 2006-08-14 2008-02-21 Biorexis Pharmaceutical Corporation Interferon beta and transferrin fusion proteins
CA2673085C (en) 2006-12-12 2013-10-15 Biorexis Pharmaceutical Corporation Transferrin fusion protein libraries
GB0711424D0 (en) * 2007-06-13 2007-07-25 Novozymes Delta Ltd Recombinant transferrin mutants
US20110124576A1 (en) * 2007-08-08 2011-05-26 Novozymes A/S Transferrin Variants and Conjugates
CA2699916A1 (en) 2007-09-18 2009-08-06 The Jackson Laboratory Antibodies and fc fusion protein modifications with enhanced persistence or pharmacokinetic stability in vivo and methods of use thereof
AU2010306940A1 (en) 2009-10-12 2012-06-07 Smith, Larry Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro
EP2512518A1 (en) 2009-12-16 2012-10-24 Novo Nordisk A/S Glp-1 receptor agonist compounds with a modified n-terminus
CN110251668A (en) 2010-11-30 2019-09-20 霍夫曼-拉罗奇有限公司 Low-affinity blood-brain barrier receptor antibody and application thereof
MX345501B (en) 2010-12-16 2017-02-02 Novo Nordisk As Solid compositions comprising a glp-1 agonist and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid.
MX355361B (en) 2011-04-12 2018-04-17 Novo Nordisk As Double-acylated glp-1 derivatives.
JP2014132832A (en) * 2011-05-10 2014-07-24 Sekisui Chem Co Ltd Medicament, functional food product, stabilization method of target protein, fusion protein, nucleic acid, and recombinant
WO2013142114A1 (en) 2012-03-19 2013-09-26 The Brigham And Women's Hosptial, Inc. Growth differentiation factor (gdf) for treatment of diastolic heart failure
MY171146A (en) 2012-03-22 2019-09-27 Novo Nordisk As Compositions of glp-1 peptides and preparation thereof
HUE042757T2 (en) 2012-03-22 2019-07-29 Novo Nordisk As Compositions comprising a delivery agent and preparation thereof
EP2863895B1 (en) 2012-06-20 2021-04-14 Novo Nordisk A/S Tablet formulation comprising a peptide and a delivery agent
KR20160029731A (en) 2013-03-12 2016-03-15 더 제너럴 하스피탈 코포레이션 Modified mullerian inhibiting substance(mis) proteins and uses thereof for the treatment of diseases
ES2945160T3 (en) 2013-03-15 2023-06-28 Gladiator Biosciences Inc Gla domains as therapeutic agents
US10092627B2 (en) 2013-04-08 2018-10-09 President And Fellows Of Harvard College Methods and compositions for rejuvenating skeletal muscle stem cells
US9815871B2 (en) 2013-04-23 2017-11-14 President And Fellows Of Harvard College Genetic reprogramming of bacterial biofilms
EP3007719B1 (en) 2013-06-11 2021-03-17 President and Fellows of Harvard College Methods and compositions for increasing neurogenesis and angiogenesis
WO2015089321A2 (en) 2013-12-11 2015-06-18 The General Hospital Corporation Use of mullerian inhibiting substance (mis) proteins for contraception and ovarian reserve preservation
CA2950589A1 (en) 2014-06-02 2015-12-10 Children's Medical Center Corporation Methods and compositions for immunomodulation
US20180258435A1 (en) 2015-04-06 2018-09-13 President And Fellows Of Harvard College Biosynthetic amyloid-based materials displaying functional protein sequences
CN108368165A (en) 2015-06-24 2018-08-03 德克萨斯大学系统董事会 For treating related indication method and composition of intracranialing hemorrhage
JP2018525021A (en) 2015-08-27 2018-09-06 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ Compositions and methods for the treatment of pain
US11098133B2 (en) 2016-05-19 2021-08-24 President And Fellows Of Harvard College Methods of making gels and films using curli nanofibers
WO2019014552A1 (en) * 2017-07-14 2019-01-17 University Of Southern California Insulin-transferrin fusion protein and its prodrug, proinsulin-transferrin, for overcoming insulin resistance
KR102647171B1 (en) 2018-02-02 2024-03-15 노보 노르디스크 에이/에스 Solid composition comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid
US11753455B2 (en) 2018-06-21 2023-09-12 Novo Nordisk A/S Compounds for treatment of obesity
US20230241171A1 (en) 2020-07-10 2023-08-03 Institut Pasteur Use of gdf11 to diagnose and treat anxiety and depression
EP4165086A4 (en) * 2020-09-16 2024-07-31 Suzhou Neologics Bioscience Co Ltd Pd-l1 antibodies, fusion proteins, and uses thereof
WO2022155410A1 (en) 2021-01-15 2022-07-21 President And Fellows Of Harvard College Methods and compositions relating to anti-mfsd2a antibodies
CN118460394B (en) * 2024-07-12 2024-09-24 通化安睿特生物制药股份有限公司 Engineering bacterium for preparing transferrin and application thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5545618A (en) * 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
WO2006017688A2 (en) * 2004-08-03 2006-02-16 Biorexis Pharmaceutical Corporation Combination therapy using transferrin fusion proteins comprising glp-1

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849293A (en) * 1996-01-11 1998-12-15 Cornell Research Foundation, Inc. Use of human transferrin in controlling insulin levels
US6458924B2 (en) * 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5545618A (en) * 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
WO2006017688A2 (en) * 2004-08-03 2006-02-16 Biorexis Pharmaceutical Corporation Combination therapy using transferrin fusion proteins comprising glp-1

Also Published As

Publication number Publication date
CA2599723A1 (en) 2006-09-14
EP1858546A2 (en) 2007-11-28
WO2006096515A2 (en) 2006-09-14
WO2006096515A3 (en) 2006-12-07
JP2008531059A (en) 2008-08-14

Similar Documents

Publication Publication Date Title
EP1858546A4 (en) Modified transferrin fusion proteins
IL189246A0 (en) Albumin fusion proteins
EP1934372A4 (en) Ssb - polymerase fusion proteins
IL222924A0 (en) Albumin fusion proteins
IL197580A0 (en) Albumin fusion proteins
IL196889A0 (en) Albumin-insulin fusion proteins
PL1830872T3 (en) Fusion proteins
GB0426397D0 (en) Fusion proteins
IL204839A0 (en) Albumin fusion proteins
ZA200709871B (en) Interferon-IgG fusion
IL196674A0 (en) Exendin fusion proteins
EP1889908A4 (en) Anti-cd14 antibody-fused protein
ZA200904757B (en) Transferrin fusion protein libraries
ZA200801224B (en) Albumin fusion proteins
GB0514482D0 (en) Protein
EP1893635A4 (en) Anchored transferrin fusion protein libraries
GB0511861D0 (en) Proteins
GB0700759D0 (en) Novel fusion protein
GB0522113D0 (en) vWFA-domain containing proteins
GB0426399D0 (en) Fusion proteins
GB0514481D0 (en) Proteins
GB0514788D0 (en) Proteins
GB0513505D0 (en) Proteins
AU2005905300A0 (en) Fusion Protein
GB0713169D0 (en) Fusion proteins

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20071004

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BIOREXIS PHARMACEUTICAL CORPORATION

A4 Supplementary search report drawn up and despatched

Effective date: 20090130

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 14/76 20060101ALI20090126BHEP

Ipc: C12P 21/02 20060101ALI20090126BHEP

Ipc: C07K 14/605 20060101ALI20090126BHEP

Ipc: A61K 38/40 20060101ALI20090126BHEP

Ipc: A61K 38/26 20060101ALI20090126BHEP

Ipc: C12N 15/63 20060101ALI20090126BHEP

Ipc: C12N 15/12 20060101AFI20090126BHEP

Ipc: C12N 15/16 20060101ALI20090126BHEP

Ipc: C12N 5/10 20060101ALI20090126BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090418